PT - JOURNAL ARTICLE AU - Liu, Wenqian AU - Wang, Nanxing AU - Yang, Mo AU - Zhang, Meiyang AU - Liu, Xiangrong AU - Shi, Kaibin AU - Liu, Weiming AU - Ou, Yunwei AU - Liu, Liping AU - Yang, Zhonghua AU - Liu, Yanfang AU - Zhou, Mengyuan AU - Liao, Xiaoling AU - Qu, Hui AU - Shi, Fu-Dong AU - Pan, Yuesong AU - Wang, Chaoyu AU - Feng, Xuezheng AU - Zhao, Xingquan AU - Zhang, Mingjun AU - Wang, Yongjun AU - Wang, Yilong TI - Intracalvariosseous injection bypasses the blood-brain barrier as a novel drug delivery approach for pre-clinical and clinical trials in stroke AID - 10.1101/2024.03.03.24303548 DP - 2024 Jan 01 TA - medRxiv PG - 2024.03.03.24303548 4099 - http://medrxiv.org/content/early/2024/03/24/2024.03.03.24303548.short 4100 - http://medrxiv.org/content/early/2024/03/24/2024.03.03.24303548.full AB - Central nervous system (CNS) accessibility constitutes a major hurdle for drug development to treat neurological diseases. Existing drug delivery methods rely integrity of the blood-brain barrier (BBB) for CNS penetration. Here we showed that the microchannels between the skull marrow and the dura mater could be harnessed for drug delivery by intracalvariosseous (ICO) injection. Drugs administered via ICO injection were found to reach cranial bone marrow-dura-perivascular space, and the injection procedure did not cause osteomyelitis or BBB damage. To validate this approach, we examined the efficacy of two neuroprotective agents, NA-1 and Y-3, via ICO injection in rat model of stroke and found that ICO injection increased drug accumulation in the brain compared to intravenous injection, reduced infarct area and alleviated neurological deficits. We subsequently conducted a clinical trial to assess the safety of ICO in acute ischemic stroke patients (ClinicalTrials.gov identifier NCT05849805), showing that ICO injection was feasible and safe in humans and its therapeutic effects may be observed. Collectively, our study identifies that the microchannels between the skull bone marrow and the dura mater act as a new channel for CNS drug delivery to achieve high intracranial drug exposure in a short period of time. The safety of ICO injection makes it a promising route of drug administration for CNS diseases.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05849805Funding StatementThis study was funded by The National Natural Science Foundation of China (No. 81825007); Beijing Outstanding Young Scientist Program (No. BJJWZYJH01201910025030); Capital special Funds for Health Improvement and Research (2022-2-2045); National Key R&D Program of China (2022YFF1501500, 2022YFF1501501, 2022YFF1501502, 2022YFF1501503, 2022YFF1501504, 2022YFF1501505); Youth Beijing Scholar Program (No.010); Beijing Laboratory of Oral Health (PXM2021_014226_000041); Beijing Talent Project: Innovation and Development (No. 2018A12); National Ten-Thousand Talent Plan” Leadership of Scientific and Technological Innovation; National Key R&D Program of China (No. 2017YFC1307900, 2017YFC1307905).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Boards(IRB) of Beijing Tiantan Hospital, Capital Medical University, Beijing, China gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.